Mark F. Gordon

Sr Dir
Teva Branded Pharmaceutical Products R&D, Inc.

L-2F - Validation of Diagnosis Algorithms for Melanoma and Nonmelanoma Skin Cancer Among Patients with Parkinson’s Disease in the United States Medicare Database
Monday, August 23, 2021
6:30 PM – 7:30 PM US Eastern Time
L-3N - The Risk of Melanoma with Rasagiline Compared with Other Antiparkinsonian Medications: A Retrospective Cohort Study in the United States Medicare Database
Tuesday, August 24, 2021
6:45 PM – 7:45 PM US Eastern Time